Patents Assigned to A&G Pharmaceutical, Inc.
-
Patent number: 11555074Abstract: The present disclosure provides an antibody, antigen binding fragment thereof, or an antibody conjugate thereof, useful in methods for treatment or diagnosis of conditions characterized by the expression of PTGFRN. The antibodies or antigen binding fragments thereof may also be used in imaging or detecting cells that express PTGFRN.Type: GrantFiled: October 15, 2018Date of Patent: January 17, 2023Assignee: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20160354452Abstract: The present invention provides materials and methods for making a subject non-responsive to an antigen. Methods of the invention may comprise contacting the subject with the antigen and a compound that induces anergy. In some embodiments, the antigen may be an autoimmune antigen, examples of which include, but are not limited to acetylcholine receptor for myasthenia gravis, glutamic acid decarboxylase for type I diabetes mellitus and rheumatoid factor in rheumatoid arthritis. In some embodiments, the present invention provides a method of transplanting an organ, tissue, or cells into a subject (e.g. a mammal such as a human).Type: ApplicationFiled: August 8, 2016Publication date: December 8, 2016Applicant: A&G PHARMACEUTICAL, INCInventor: Jun HAYASHI
-
Patent number: 8911950Abstract: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.Type: GrantFiled: August 29, 2011Date of Patent: December 16, 2014Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 8512960Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.Type: GrantFiled: September 26, 2008Date of Patent: August 20, 2013Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20120087918Abstract: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.Type: ApplicationFiled: August 29, 2011Publication date: April 12, 2012Applicant: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 8088373Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: GrantFiled: June 19, 2008Date of Patent: January 3, 2012Assignee: A&G Pharmaceutical, Inc.Inventors: Ginette Serrero, Le Sun
-
Publication number: 20110223623Abstract: The invention provides methods for prognosis of patients afflicted with cancer, comprising determining the level of GP88 expression in a biological sample obtained from said patient.Type: ApplicationFiled: September 8, 2009Publication date: September 15, 2011Applicant: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 8007997Abstract: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.Type: GrantFiled: April 8, 2009Date of Patent: August 30, 2011Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 7815906Abstract: Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens, and therapeutic compositions comprising an HER2 antagonist and a PCDGF antagonist.Type: GrantFiled: June 18, 2008Date of Patent: October 19, 2010Assignee: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20100111928Abstract: Methods and kits for diagnosing tumorigenicity by measuring the concentration of GP88 in blood, plasma, serum, saliva, urine and other biological fluids. The methods and kits detect GP88 in biological fluids at a concentration as low as about 0.1 to 10 nanograms per milliliter and are useful for determining whether a patient has a tumorigenic condition, whether the patient is likely to be responsive to anti-tumorigenic therapies, and whether the treated patient is responding to anti-tumorigenic therapy by measuring the concentration of GP88 in the patient's serum or other biological fluid.Type: ApplicationFiled: October 16, 2008Publication date: May 6, 2010Applicant: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 7674460Abstract: Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens, and therapeutic compositions comprising an HER2 antagonist and a PCDGF antagonist.Type: GrantFiled: July 30, 2004Date of Patent: March 9, 2010Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20100021475Abstract: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.Type: ApplicationFiled: April 8, 2009Publication date: January 28, 2010Applicant: A & G PHARMACEUTICAL, INC.Inventor: GINETTE SERRERO
-
Patent number: 7651854Abstract: Disclosed herein are methods of increasing the proliferation of non-tumorigenic B cells. The methods involve administering PCDGF and optionally other B cells stimulators (e.g., IgM, LPS) to B cells resulting in an increase in B cell proliferation. The methods of the invention can be used, for example, to establish B cells lines, to sort B cells from a mixed population of cells, or to activate resting B cells.Type: GrantFiled: December 17, 2003Date of Patent: January 26, 2010Assignee: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 7592318Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.Type: GrantFiled: June 30, 2003Date of Patent: September 22, 2009Assignee: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20090203047Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.Type: ApplicationFiled: September 26, 2008Publication date: August 13, 2009Applicant: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 7560095Abstract: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the antigen and the CDR regions of the antibody are also disclosed, as well as methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.Type: GrantFiled: April 22, 2004Date of Patent: July 14, 2009Assignee: A & G Pharmaceutical, Inc.Inventors: Le Sun, Ginette Serrero, Joe Corvera, Yudong Hou
-
Publication number: 20090010931Abstract: Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens, and therapeutic compositions comprising an HER2 antagonist and a PCDGF antagonist.Type: ApplicationFiled: June 18, 2008Publication date: January 8, 2009Applicant: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Publication number: 20080311120Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: ApplicationFiled: June 19, 2008Publication date: December 18, 2008Applicant: A&G Pharmaceutical, Inc.Inventors: Ginette Serrero, Le Sun
-
Patent number: 7411045Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: GrantFiled: November 19, 2002Date of Patent: August 12, 2008Assignee: A&G Pharmaceutical, Inc.Inventors: Ginette Serrero, Le Sun
-
Patent number: 7368428Abstract: Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells to GP88 antagonists (e.g., anti-GP88 antibodies, anti-GP88 antisense nucleic acids, GP88 siRNA, and small molecules) induces apoptosis and restores sensitivity to the antitumorigenic effects of antiestrogen therapy and cytotoxic therapy.Type: GrantFiled: June 23, 2004Date of Patent: May 6, 2008Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero